Business
Dyadic Announces Third Quarter 2020 Financial Results and Highlights Recent Company Progress
Six new and expanded animal and human health collaborations since Q2 2020Expanded presence in the Asia Pacific RegionImportant progress and expanded animal
About this update from Dyadic International, Inc.
[{"type":"text","content":"Six new and expanded animal and human health collaborations since Q2 2020Expanded presence in the Asia Pacific RegionImportant progress and expanded animal efficacy data in COVID-19 vaccine and antibody programs ZAPI to conduct additional animal studies for Schmallenberg Virus (SBV) and initiate animal studies for Rift Valley Fever Virus (RVFV)Continued strong financial position at end of third quarterJUPITER, FL / ACCESSWIRE / November 12, 2020 / Dyadic International, Inc. (\"Dyadic\") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced its financial results for the quarter ended September 30, 2020, and recent developments.\"We continued to advance our proprietary C1 gene expression platform into a safe and efficient expression system, with improved properties and impressive scientific results,\" stated Mark Emalfarb, Dyadic's Chief Executive Officer. \"Our business development pipeline continues to grow with additional interest from both new and previously engaged collaborators, which we believe will accelerate the adoption of our C1 gene expression platform toward the goal of commercialization. In addition to our COVID-19 initiatives, we signed six new and expanded collaborations with human and animal health companies. Additionally, we are expanding our presence in the Asia Pacific region with the signing of a research collaboration agreement with Jiangsu Hengrui Medicine, the largest pharmaceutical company in China (by market capitalization), and our previously announced, non-exclusive, research collaboration with WuXi Biologics, a leading global CDMO.\"\"With respect to our COVID-19 programs, we are currently working with nine groups, including the Israel Institute for Biological Research (\"IIBR\"), the European ZAPI scientists, scientists from Oxford University among others, and we anticipate that up to ten animal trials will be completed by, or shortly after, year-end. This is in addition to the Frederick National Laboratory project that we announced in June, which is ongoing and showing encouraging expression data. Importantly, there will be trials with mice, hamsters and ACE2 transgenic ...